Company intelligence / Profile preview

InCircle

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

InCircle AB was a Swedish biotechnology company focused on developing improved formulations of established oncology therapeutics to enhance efficacy and reduce toxicity. The company's lead asset was Doxophos, a micellar formulation of the chemotherapy agent doxorubicin, which utilized a proprietary drug delivery technology to improve solubility and targeting. InCircle was acquired in 2016 by Oasmia Pharmaceutical (now Vivesto) to integrate Doxophos into its oncology pipeline. The acquisition allowed for the further development of Doxophos alongside other micellar chemotherapy products like Apealea.

Therapeutic areas: Oncology
Modalities: Small moleculeNanoparticle
Industry: Biotech

Beyond the preview

Go deeper on InCircle.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InCircle.

Explore the full profile